BESands, et al.  Inflammatory Bowel Diseases, 2024. 30: 2024 2245–2258. Open Access! Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

In this LUCENT-3 study, the authors examined response at 2 years among patients who had response to treatment at 1 year; patients received 200 mg mirikizumab every 4 weeks. The authors stratified patients by induction response and by previous biologic exposure.

Key findings (from Figure 4):

• No new safety signals were identified, and the discontinuation rate due to adverse events was 2.8%

My take: It is good to see extended data for mirkizumab. Head-to-head trials, though, are needed to better determine which therapies are most effective.

Related blog posts:

• New Therapy for Crohn’s Disease: Mirikizumab
• IBD Updates: Extending Mirkizumab Induction, Best Biologic, Fatigue in Pediatric IBD, Adalimumab Success in Patients with Abdominal Abscess
• IBD Updates: Dual Advanced Therapies in Pediatrics, IL23 agents/Psoriasis
• Risankizumab for Ulcerative Colitis